Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biogen Inc (BIIB)

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 50,113,096
  • Shares Outstanding, K 163,187
  • Annual Sales, $ 14,378 M
  • Annual Income, $ 5,889 M
  • 60-Month Beta 0.54
  • Price/Sales 3.49
  • Price/Cash Flow 7.95
  • Price/Book 4.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 7.97
  • Number of Estimates 29
  • High Estimate 8.92
  • Low Estimate 6.87
  • Prior Year 9.15
  • Growth Rate Est. (year over year) -12.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
291.83 +5.23%
on 05/27/20
335.00 -8.33%
on 05/12/20
+2.38 (+0.78%)
since 04/29/20
3-Month
262.25 +17.10%
on 03/23/20
350.24 -12.32%
on 04/20/20
-1.30 (-0.42%)
since 02/28/20
52-Week
215.77 +42.32%
on 09/04/19
374.99 -18.11%
on 02/05/20
+83.69 (+37.46%)
since 05/29/19

Most Recent Stories

More News
FDA Okays Lilly's Alzheimer's Disease Diagnostic Agent Tauvid

With the US regulatory agency's nod, Eli Lilly's (LLY) Tauvid became the first and the only approved radioactive diagnostic agent to image tau NFTs in the brain for effectively evaluating AD patients.

BIIB : 307.09 (+2.19%)
RHHBY : 43.3500 (-1.37%)
MRK : 80.72 (+2.13%)
LLY : 152.95 (+1.53%)
Veeva Systems (VEEV) Q1 Earnings and Revenues Beat Estimates

Veeva Systems' (VEEV) core Subscription business segment performed impressively in Q1.

BIIB : 307.09 (+2.19%)
LLY : 152.95 (+1.53%)
VEEV : 218.87 (+7.18%)
APHA : 4.23 (-1.86%)
Vir Biotechnology and Biogen Execute Agreement to Manufacture SARS-CoV-2 Antibodies for Potential COVID-19 Treatment

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that is has finalized a process development and manufacturing agreement with Biogen Inc. (Nasdaq: BIIB) based on the letter of intent that the companies...

VIR : 34.18 (+8.30%)
BIIB : 307.09 (+2.19%)
Bristol-Myers (BMY) Wins EC Approval for MS Drug Zeposia

Bristol-Myers (BMY) gets EC nod for Zeposia for the treatment of adult patients with relapsing remitting multiple sclerosis.

BIIB : 307.09 (+2.19%)
MRK : 80.72 (+2.13%)
BMY : 59.72 (-0.15%)
XLRN : 98.83 (-0.19%)
Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science

- The online learning program combines lab simulations and mentoring experiences focused on biotechnology and neurological diseases, such as Parkinson's disease, Alzheimer's disease and multiple sclerosis...

BIIB : 307.09 (+2.19%)
Top Analyst Reports for Alibaba, Chevron & Shopify

Top Analyst Reports for Alibaba, Chevron & Shopify

WBA : 42.94 (+2.65%)
SHOP : 757.80 (+1.80%)
DUK : 85.63 (-0.23%)
CVX : 91.70 (+0.91%)
BIIB : 307.09 (+2.19%)
BABA : 207.39 (+3.96%)
Veeva Systems (VEEV) to Post Q1 Earnings: What's in Store?

Veeva Systems' (VEEV) fiscal first-quarter results are likely to reflect solid show by its segments and robust product portfolio.

BIIB : 307.09 (+2.19%)
LLY : 152.95 (+1.53%)
VEEV : 218.87 (+7.18%)
APHA : 4.23 (-1.86%)
Medtronic (MDT) Q4 Earnings Miss Estimates, Revenues Beat

Medtronic (MDT) demonstrates weak fiscal fourth-quarter performances at CER, attributable to dismal show in all major business segments and geographies.

BIIB : 307.09 (+2.19%)
MDT : 98.58 (+0.45%)
LLY : 152.95 (+1.53%)
APHA : 4.23 (-1.86%)
McKesson (MCK) Q4 Earnings and Revenues Surpass Estimates

McKesson's (MCK) fiscal fourth-quarter 2020 results benefit from strong segmental performance.

BIIB : 307.09 (+2.19%)
MCK : 158.67 (+1.15%)
LLY : 152.95 (+1.53%)
APHA : 4.23 (-1.86%)
Zacks.com featured highlights include: Graphic Packaging, Canadian Solar, Biogen and Vistra Energy

Zacks.com featured highlights include: Graphic Packaging, Canadian Solar, Biogen and Vistra Energy

BIIB : 307.09 (+2.19%)
CSIQ : 18.80 (+3.64%)
GPK : 14.47 (-0.41%)
VST : 20.44 (-1.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade BIIB with:

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Key Turning Points

2nd Resistance Point 314.18
1st Resistance Point 310.64
Last Price 307.09
1st Support Level 300.73
2nd Support Level 294.36

See More

52-Week High 374.99
Fibonacci 61.8% 314.17
Last Price 307.09
Fibonacci 50% 295.38
Fibonacci 38.2% 276.60
52-Week Low 215.77

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar